查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1378788

2023-2028 年青光眼治療市場報告（依藥物類別、適應症、最終使用者和地區）

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2023-2028
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年，全球青光眼治療市場規模達到74億美元。展望未來， IMARC Group預計到2028年市場規模將達到108億美元，2022-2028年複合年成長率（CAGR）為6.5%。青光眼在全球範圍內的盛行率不斷上升、早期檢測診斷技術的不斷進步、眼科遠距醫療的日益普及以及外科手術中的眾多技術創新是推動市場發展的一些因素。

青光眼是一組導致視神經損傷的眼部疾病，可導致視力喪失。這些干預措施通常透過藥物、雷射治療或手術進行管理，旨在降低眼內壓（IOP），眼內壓是青光眼進展的關鍵因素。青光眼治療通常包括前列腺素、BETA受體阻斷劑和α受體激動劑等藥物，通常以眼藥水形式給藥，目標是減少眼液產生或改善其流出。雷射治療（例如小梁成形術）是另一種方法，其中雷射光束聚焦在眼睛的引流系統上以促進液體排出。小梁切除術和引流植入手術等外科手術是創造液體引流替代通道的最終手段。這些療法可以單獨使用，也可以組合使用，這取決於青光眼的嚴重程度和類型。

全球市場主要是由全球青光眼盛行率不斷上升所推動的，特別是在老年族群。與此一致的是，早期檢測診斷技術的不斷進步正在為市場提供動力。此外，新藥物輸送方法的開發是重要的生長誘導因素。除此之外，製藥公司加大研發投資正在為市場創造新的途徑。除此之外，人們越來越意識到定期眼科檢查和及時治療青光眼症狀的重要性，這鼓勵了這些療法的採用。此外，衛生組織傳播青光眼知識的措施也對市場產生了正面影響。除此之外，專業眼科護理中心數量的成長正在推動市場。對該市場做出貢獻的其他一些因素包括獲得醫療保健的中產階級人口不斷擴大、對個人化醫療的日益關注以及創新治療產品的推出。

青光眼治療市場趨勢/促進因素：

手術過程中的眾多技術創新

外科手術技術創新的出現對全球市場產生了重大影響。最具突破性的進展之一是微創青光眼手術（MIGS）。事實證明，這些手術干預措施具有變革性，因為與小梁切除術等傳統手術方法相比，併發症更少，恢復時間更短，並且更容易實施。 MIGS 的簡單性為外科醫生提供了更多選擇來有效管理疾病，同時最大限度地減少患者的潛在風險和不適。此外，微型支架和新型引流系統等外科醫療器材的進步進一步提高了青光眼手術的效果。這些進步反過來又增加了全球醫療保健從業者和患者對手術解決方案作為青光眼可行治療選擇的信任。

眼科遠距醫療的採用率不斷上升

遠距醫療已日益成為醫療保健不可或缺的一部分，當涉及青光眼治療市場時，其在眼科的應用尤其值得關注。醫療數位化，加上軟硬體技術的進步，使得遠距會診變得實用且有效。現在患者可以監測自己的病情，而無需頻繁去醫院，這對於居住在農村或偏遠地區的患者尤其有利。醫療保健服務範圍的擴大提高了患者的參與度，從而有助於取得更好的結果。遠距會診可以實現持續監控，即時資料可以提醒醫療保健提供者註意患者病情的變化，可能需要立即干涉。增強的資料收集能力也為研究提供了前所未有的機會，從而有可能加速新治療方式的發展。

更重視病人照護的整體方法

綜合的整體治療計劃通常涉及多學科的醫療保健提供者團隊，包括營養師、物理治療師和心理諮商師等。這不僅為患者提供了更全面的治療計劃，而且還開啟了醫療保健生態系統內的交叉銷售和追加銷售機會。重點已經從治療症狀轉向更全面的方法，同時考慮患者教育、生活方式的改變和預防措施以及醫療干預措施。整體方法也認知到飲食、運動和壓力管理等生活方式因素在治療青光眼中的作用。對患者進行有關有助於降低眼內壓的食物類型和活動的教育，眼內壓是青光眼的關鍵因素。這種多管齊下的方法不僅提高了醫療效果，而且改善了患者的整體生活品質。

青光眼治療行業細分：

IMARC Group提供了全球青光眼治療市場報告各細分市場主要趨勢的分析，以及 2023-2028 年全球、區域和國家層面的預測。我們的報告根據藥物類別、適應症和最終用戶對市場進行了分類。

按藥物類別細分：

前列腺素類似物

BETA受體阻斷劑

α腎上腺素激動劑

碳酸酐酶抑制劑

複方藥物

其他

前列腺素類似物代表最大的細分市場

該報告根據藥物類別提供了詳細的市場細分和分析。這包括前列腺素類似物、BETA受體阻斷劑、α腎上腺素激動劑、碳酸酐酶抑制劑、組合藥物等。根據該報告，前列腺素類似物代表了最大的部分。

前列腺素類似物市場的主要驅動力是其降低眼壓的功效，與其他類別的青光眼藥物相比，其全身副作用較少。這些藥物每日一次給藥的便利性也有助於提高患者的依從性，從而增加其市場需求。配方和輸送機制的創新是其市場佔有率的另一個主要因素。然而，智慧財產權到期和隨後學名藥的進入對市場成長構成了挑戰。最後，它們與其他類別的青光眼藥物的多功能兼容性使它們成為聯合療法的首選，從而增強了該領域的突出地位。

另一方面，BETA受體阻斷劑、α腎上腺素激動劑、碳酸酐酶抑制劑、組合藥物和其他細分市場受到多種因素的影響，例如可負擔性、不同的作用機制和完善的安全性。這些藥物通常在前列腺素類似物禁忌或無效的情況下使用。儘管它們有效，但每日多次給藥的需要可能會影響患者的依從性。此類學名藥的可用性也使其成為具有成本效益的治療選擇。

按指示細分：

開角型青光眼

閉角型青光眼

其他

開角型青光眼代表最大的細分市場

該報告根據該指標提供了詳細的市場細分和分析。這包括開角型青光眼、閉角型青光眼等。根據該報告，開角型青光眼佔最大部分。

開角型青光眼的發生率主要是由其盛行率推動的，佔全球青光眼病例的大多數。認知的提高和診斷技術的進步使得這種情況的檢測更早、更頻繁。從藥物到手術等多種治療方案的出現，為治療開角型青光眼提供了綜合方法。人口老化進一步提高了發病率，從而推動了對治療產品的需求。政府針對眼睛健康的措施有助於該細分市場的整體市場成長。

另一方面，閉角型青光眼和其他疾病的成長主要是由人口老化所驅動的，因為這種情況在老年人中更為普遍。診斷技術的進步也有助於更早、更準確地檢測病情，從而促進了該領域的擴張。此外，人們對未經治療的閉角型青光眼（可能導致失明）嚴重性的認知不斷提高，導致對有效治療的需求更高。

按最終用戶分類：

醫院

眼科診所

門診手術中心

其他

醫院佔大部分市場佔有率

該報告提供了基於最終用戶的詳細市場細分和分析。這包括醫院、眼科診所、門診手術中心等。報告稱，醫院佔最大部分。

醫院是青光眼治療市場的主要消費者，因為它們有能力提供先進的診斷和手術介入。醫療保健設施的整合和對最先進眼科部門的投資促進了該領域的成長。此外，醫院通常是緊急眼科疾病的第一個接觸點，因此將它們定位為重要的利害關係人。公共和私人保險範圍也鼓勵在醫院環境中進行治療，增加患者吞吐量和青光眼藥物的消耗量。

另一方面，眼科診所、門診手術中心和其他細分市場的成長可歸因於對眼科護理的專門關注、先進診斷設備的可用性以及更快的患者周轉率。消費者對專業照護的偏好不斷增加也是一個因素。醫療保健服務的分散化和門診手術中心的擴張使得這些設施可以進行小手術和定期檢查。靈活的支付方式和更短的等待時間進一步支持了成長。

按地區分類：

北美洲

美國

加拿大

亞太地區

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美表現出明顯的主導地位，佔據最大的青光眼治療市場佔有率

市場研究報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美佔據最大的市場佔有率。

北美地區的市場受到高額醫療保健支出、穩健的保險框架以及領先製藥公司的存在的顯著推動。此外，該地區人口多樣化且老化，從而產生了對青光眼治療的自然需求。在研發方面的大量投資的支持下，藥物配方和輸送方面的技術進步也推動了市場的成長。

加速核准和撥款方面的監管支援可促進創新，為市場擴張提供有利的環境。政府在醫療保健教育和眼科篩檢方面的措施有助於早期診斷，進而推動對治療的需求。專業眼科診所和門診手術中心的便利性又增加了一層便利，鼓勵及時介入。

品牌藥和學名藥的供應提供了不同價位的選擇，迎合了廣泛的消費者群體。此外，公共和私營部門在醫療保健措施方面的合作有助於提高意識並促進新型治療解決方案進入和接受市場。

競爭格局：

市場上的主要參與者一直致力於開發更有效、更侵入性的治療方案。他們正在大量投資於臨床試驗，以生產能夠提供更持久緩解且副作用更少的藥物和設備。與研究機構和醫療保健組織的合作是這些關鍵參與者的常見策略。市場領導者也透過推出專門設計用於治療不同類型青光眼的創新產品來擴大其產品組合。此外，這些公司正在努力滿足嚴格的監管要求，確保其產品安全有效。此外，他們還注重患者教育和意識計劃，作為其市場擴張策略的一部分。

該報告對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。市場上的一些主要參與者包括：

艾利藥廠

艾爾建公司

博士倫公司（博士倫健康公司）

艾諾泰克製藥公司

默克公司

諾華公司

輝瑞公司

參天製藥股份有限公司

SIFI公司

梯瓦製藥工業股份有限公司

最近的發展：

2022 年 11 月，Aerie Pharmaceuticals, Inc. 被全球眼科護理領導者愛爾康收購。透過此交易，愛爾康新增了商業產品Rocklatan（奈達舒地爾和拉坦前列素眼藥水）0.02%/0.005%和Rhopressa（奈達舒地爾眼藥水）0.02%、AR-15512 ，這是一種治療乾眼症的3期候選產品，也是一條管道眼科藥品候選者。

2023 年7 月，Bausch Health Companies Inc. 宣布，Bausch Health 的全資子公司、安大略省有限合夥企業Bausch Receivables Funding LP 已與KKR 及其信貸基金和帳戶簽訂了6 億美元的無追索權融資協議。該貸款將以 Bausch Health 全資子公司產生的某些應收帳款作為抵押。

默克宣布，歐盟委員會 (EC) 已批准默克的抗 PD-1 療法 KEYTRUDA 與曲妥珠單抗、氟嘧啶和含鉑化療聯合用於局部晚期不可切除或轉移性人類的一線治療腫瘤表達PD-L1 的成人表皮生長因子受體2 (HER2) 陽性胃或胃食道交界處(GEJ) 腺癌（綜合陽性評分[CPS] ≥1）。

本報告回答的關鍵問題

  • 全球青光眼治療市場有多大
  • 2023-2028年全球青光眼治療市場的預期成長率是多少
  • 推動全球青光眼治療市場的關鍵因素是什麼
  • COVID-19 對全球青光眼治療市場有何影響
  • 根據藥物類別，全球青光眼治療市場的細分如何
  • 根據適應症，全球青光眼治療市場的細分如何
  • 基於最終用戶的全球青光眼治療市場的細分是什麼
  • 全球青光眼治療市場的關鍵區域有哪些
  • 誰是全球青光眼治療市場的主要參與者/公司

本報告回答的關鍵問題

  • 全球青光眼治療市場有多大？
  • 2023-2028年全球青光眼治療市場的預期成長率是多少？
  • 推動全球青光眼治療市場的關鍵因素是什麼？
  • COVID-19 對全球青光眼治療市場有何影響？
  • 根據藥物類別，全球青光眼治療市場的細分如何？
  • 根據適應症，全球青光眼治療市場的細分如何？
  • 基於最終用戶的全球青光眼治療市場的詳細情形如何？
  • 全球青光眼治療市場的關鍵區域有哪些？
  • 誰是全球青光眼治療市場的主要參與者/公司？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球青光眼治療市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按藥物類別分類的市場細分

  • 前列腺素類似物
    • 市場走向
    • 市場預測
  • BETA受體阻斷劑
    • 市場走向
    • 市場預測
  • α腎上腺素激動劑
    • 市場走向
    • 市場預測
  • 碳酸酐酶抑制劑
    • 市場走向
    • 市場預測
  • 複方藥物
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：按跡象分類的市場

  • 開角型青光眼
    • 市場走向
    • 市場預測
  • 閉角型青光眼
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：最終用戶的市場區隔

  • 醫院
    • 市場走向
    • 市場預測
  • 眼科診所
    • 市場走向
    • 市場預測
  • 門診手術中心
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：按地區分類的市場區隔

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太地區
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Aerie Pharmaceuticals Inc.
    • Allergan Plc
    • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
    • Inotek Pharmaceuticals Corp.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Santen Pharmaceutical Co. Ltd.
    • SIFI SpA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112023A2770

Abstract

The global glaucoma therapeutics market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.5% during 2022-2028. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.

Glaucoma is a group of eye conditions resulting in optic nerve damage, which can lead to vision loss. Typically managed through medications, laser treatment, or surgery, these interventions aim to reduce intraocular pressure (IOP), which is a key factor in glaucoma progression. Glaucoma therapeutics typically include medications such as prostaglandins, beta-blockers, and alpha agonists are commonly administered in eye drop form, targeting the reduction of eye fluid production or its improved outflow. Laser treatment, such as trabeculoplasty, is another method where laser beams focus on the eye's drainage system to facilitate fluid exit. Surgical procedures like trabeculectomy and drainage implant surgery are the final resorts to create alternative channels for fluid drainage. These therapeutics are used either in isolation or in combinations depending on the severity and type of glaucoma.

The global market is primarily driven by the growing prevalence of glaucoma across the globe, particularly among the geriatric population. In line with this, continual advancements in diagnostic technologies for early detection are providing an impetus to the market. Moreover, the development of new drug delivery methods is acting as a significant growth-inducing factor. In addition to this, increased investment in research and development by pharmaceutical companies is creating new avenues in the market. Besides this, the rising awareness about the importance of regular eye check-ups and timely treatment of glaucoma symptoms is encouraging the adoption of these therapeutics. Also, initiatives by health organizations to disseminate knowledge about glaucoma are positively impacting the market. Apart from this, growth in the number of specialized eye care centers is propelling the market. Some of the other factors contributing to the market include an expanding middle-class population with access to healthcare, a growing focus on personalized medicine, and the introduction of innovative therapeutic products.

Glaucoma Therapeutics Market Trends/Drivers:

Numerous technological innovation in surgical procedures

The advent of technological innovation in surgical procedures has significantly influenced the global market. One of the most groundbreaking developments is Minimally Invasive Glaucoma Surgeries (MIGS). These surgical interventions have proved to be transformative by causing fewer complications, necessitating shorter recovery periods, and being easier to perform than traditional surgical methods like trabeculectomy. The ease of MIGS has empowered surgeons with more options to manage the disease effectively while minimizing the potential risks and discomfort to the patient. In addition, advancements in surgical medical devices such as micro-stents and new drainage systems have further improved the effectiveness of glaucoma surgeries. These advancements have, in turn, increased the trust among healthcare practitioners and patients across the globe in surgical solutions as viable treatment options for glaucoma.

Rising adoption of telemedicine in ophthalmology

Telemedicine has increasingly become an integral part of healthcare, and its applications in ophthalmology are particularly noteworthy when it comes to the glaucoma therapeutics market. The digitalization of healthcare, coupled with technological advancements in software and hardware, has made remote consultations both practical and effective. Patients can now have their conditions monitored without the need for frequent hospital visits, which is especially beneficial for those residing in rural or remote locations. This wider reach of healthcare services enhances patient engagement, thereby contributing to better outcomes. Remote consultations enable continuous monitoring, and real-time data can alert healthcare providers to changes in a patient's condition that may require immediate intervention. The enhanced data collection capabilities also offer unprecedented opportunities for research, thereby potentially accelerating the development of new treatment modalities.

An enhanced focus on holistic approaches to patient care

An integrated, holistic treatment plan often involves a multi-disciplinary team of healthcare providers, including nutritionists, physiotherapists, and psychological counselors, among others. This not only gives patients a more comprehensive treatment plan but also opens up cross-selling and up-selling opportunities within the healthcare ecosystem. The focus has moved beyond treating the symptoms to a more integrated approach, taking into account patient education, lifestyle changes, and preventive measures alongside medical interventions. A holistic approach also recognizes the role of lifestyle factors such as diet, exercise, and stress management in managing glaucoma. Patients are educated about the types of foods and activities that can help in reducing intraocular pressure, which is a critical factor in glaucoma. This multi-pronged approach not only enhances the effectiveness of medical treatments but also improves the overall quality of life for the patients.

Glaucoma Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global glaucoma therapeutics market report, along with forecasts at the global, regional, and country levels for 2023-2028. Our report has categorized the market based on drug class, indication and end user.

Breakup by Drug Class:

Prostaglandin Analogs

Beta Blockers

Alpha Adrenergic Agonists

Carbonic Anhydrase Inhibitors

Combination Drugs

Others

Prostaglandin analogs represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes prostaglandin analogs, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and others. According to the report, prostaglandin analogs represented the largest segment.

The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.

On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.

Breakup by Indication:

Open Angle Glaucoma

Angle Closure Glaucoma

Others

Open angle glaucoma represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the indication. This includes open angle glaucoma, angle closure glaucoma and others. According to the report, open angle glaucoma represented the largest segment.

The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving demand for therapeutic products. Government initiatives aimed at eye health contribute to the overall market growth for this segment.

On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.

Breakup by End User:

Hospitals

Ophthalmic Clinics

Ambulatory Surgery Centers

Others

Hospitals accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ophthalmic clinics, ambulatory surgery centers and others. According to the report, hospitals represented the largest segment.

Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.

On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel market growth.

Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.

The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.

Competitive Landscape:

The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Aerie Pharmaceuticals Inc.

Allergan Plc

Bausch & Lomb Incorporated (Bausch Health Companies Inc.)

Inotek Pharmaceuticals Corp.

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Santen Pharmaceutical Co. Ltd.

SIFI S.p.A

Teva Pharmaceutical Industries Ltd

Recent Developments:

In November 2022, Aerie Pharmaceuticals, Inc. was acquired by Alcon, the global leader in eye care. Through the transaction, Alcon has added the commercial products Rocklatan(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa(netarsudil ophthalmic solution) 0.02%, AR-15512, a Phase 3 product candidate for dry eye disease and also a pipeline of ophthalmic pharmaceutical product candidates.

In July 2023, Bausch Health Companies Inc. announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health.

Merck & Co. announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1).

Key Questions Answered in This Report

  • 1. How big is the global glaucoma therapeutics market?
  • 2. What is the expected growth rate of the global glaucoma therapeutics market during 2023-2028?
  • 3. What are the key factors driving the global glaucoma therapeutics market?
  • 4. What has been the impact of COVID-19 on the global glaucoma therapeutics market?
  • 5. What is the breakup of the global glaucoma therapeutics market based on the drug class?
  • 6. What is the breakup of the global glaucoma therapeutics market based on the indication?
  • 7. What is the breakup of the global glaucoma therapeutics market based on the end user?
  • 8. What are the key regions in the global glaucoma therapeutics market?
  • 9. Who are the key players/companies in the global glaucoma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Prostaglandin Analogs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Beta Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alpha Adrenergic Agonists
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Combination Drugs
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ophthalmic Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aerie Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Allergan Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Inotek Pharmaceuticals Corp.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Santen Pharmaceutical Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SIFI S.p.A
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2022
  • Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2022
  • Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2022
  • Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
  • Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
  • Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
  • Table 7: Global: Glaucoma Therapeutics Market: Key Players